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signiﬁcant difference against CD20- control cells: RS4;11 and
Jurkat.
Consistently, intracellular CD107a degranulation was
enhanced in CAR+ exPBNK compared to CAR- exPBNK in
response to CD20+ Ramos.
MIC expressionwas signiﬁcantly increased in Ramos (P< .05)
and in NALM-6 (P < .001) after romidepsin treatment.
CD20 expression was signiﬁcantly increased in NALM-6 (P <
.001) after romidepsin treatment.
CAR+ exPBNK in vitro cytotoxicity was signiﬁcantly enhanced
against romidepsin treated Ramos (P< .02) and NALM-6 (P<
.01) compared to untreated targets.
Conclusion: Anti-CD20 CAR expression in exPBNK cells
results in signiﬁcant and speciﬁc in vitro cytotoxicity against
CD20+ B-L/L. Romidepsin increases MICA/B and CD20
expression in B-L/L. CAR exPBNK signiﬁcantly enhanced
cytotoxicity against romidepsin treated B-L/L. Future direc-
tions include examining the combination effect of CAR
exPBNK and Romidepsin against B-L/L in xenograft mice.411
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T cell depletion (TCD) by negative or positive selection
reduces graft-vs-host disease and its complications while
maintaining relapse free survival in appropriately selected
patients. Differences in acute GVHD incidence of sibling
donor transplants using 3 TCDmethods stimulated review of
graft content. Graft source (bone marrow [BM] or peripheral
blood stem cells [PBSC]) and TCD method determine cell
composition, impacting outcome and survival. As a center
historically committed to TCD, we reviewed 531 TCD grafts
processed in 2000-2011 using 3 TCD methods for BM or
PBSC. Pre and postprocessing cell composition, log10 TCD,
and % CD34+ recovery were compared. BM, negatively
selected by soybean lectin agglutination and sheep RBC
rosetting (SBA-E-) was used in 76 patients; PBSC, positively
selected for CD34+ cells by the Isolex followed by RBCTable
Median Cell Dose/kg Pre and Post TCD
Cells TNC CD34 CD3
Pre BM 3.81E+08 5.87E+06 2.69E+07
Pre PBSC 1.19E+09 8.72E+06 2.38E+08
SBA-E- 2.84E+07 1.86E+06 6.07E+04
Iso E- 7.63E+06 7.31E+06 1.58E+03
Clini 8.53E+06 1.05E+07 3.56E+03rosetting (IsoE-) for 361 patients, or by the CliniMACS (Clini),
for 94 patients. The table shows preprocessing cell doses and
phenotypic proﬁle were signiﬁcantly different between pre
BM and pre PBSC for TNC, CD3+T cells, T cell subsets, NK cells
and CD34+ (P-values < .001, Wilcoxon rank-sum test). BM T
cells had a 1:1 ratio of CD4:CD8 while PBSC had a 1:2 ratio.
The table shows post TCD T cell doses were signiﬁcantly
higher in BM than in PBSC grafts. In TCD BM, the median log
10 depletion of CD3 + T cells (2.65) was signiﬁcantly different
from IsoE log10 TCD (5.22). Clini log 10 TCD (4.92) was
similar to IsoE. Strikingly, while preprocessed BM had fewer
NK CD56/16+ than PBSC (3.86E+06 vs. 3.59E+07), the nega-
tive selection of BM left more NK cells in the TCD graft,
resulting in signiﬁcantly higher NK cell dose (6.73E+05) than
after CD34+ positive selection by Iso E- (2.25E+03) or Clini
(6.98E+02). IsoE- had signiﬁcantly (P < .001) higher CD34
doses (7.31E+06 /kg) and greater recovery (85.0%) of CD34+
cells; than SBA-E- (1.86E+06 /kg, 33.3% recovery). Clini
selection resulted in similar CD34 cell doses and recovery to
the IsoE-. (1.05E+07/kg, 116.74 % recovery). Number and
types of CD3+ T cells, T subpopulations, NK, and CD34+ in
TCD grafts act in concert with donor and host parameters to
effect ﬁnal transplant outcome. Characterization of cells in
preprocessed grafts and retained by TCDmethods can lead to
better graft engineering and optimization of the cellular
content of the ﬁnal T depleted product.412
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